Intentional overdose of dolutegravir/abacavir/lamivudine (Triumeq) in a 26-year-old man

Paul van Dam; Mark van Geffen; Thomas Havenith; Dirk Posthouwer

doi:10.3851/IMP3229

Intentional overdose of dolutegravir/abacavir/lamivudine (Triumeq) in a 26-year-old man

Paul van Dam^*, Mark van Geffen, Thomas Havenith, Dirk Posthouwer

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

Abstract

Triumeq is a single-tablet regimen for patients with HIV infection comprising dolutegravir, abacavir and lamivudine. Overdoses with Triumeq have not been reported previously. We present a case of a 26-year-old man who presented to our hospital after intentionally ingesting 30 tablets of Triumeq. An intoxication with Triumeq can lead to several side effects. An overdose of abacavir and lamivudine can cause mitochondrial toxicity and lactic acidosis. An intoxication with dolutegravir appears to be relatively harmless. As Triumeq will be used on a regular basis as treatment for patients with HIV-1 infection, these intoxications are expected to be encountered more often.

Original language	English
Pages (from-to)	549-552
Number of pages	4
Journal	Antiviral Therapy
Volume	23
Issue number	6
DOIs	https://doi.org/10.3851/IMP3229
Publication status	Published - 2018

Keywords

POPULATION PHARMACOKINETICS
HIV
FUMARATE/EMTRICITABINE
DOLUTEGRAVIR

Access to Document

10.3851/IMP3229

Cite this

@article{31ff638ca535421dbd7541ef62b32389,

title = "Intentional overdose of dolutegravir/abacavir/lamivudine (Triumeq) in a 26-year-old man",

abstract = "Triumeq is a single-tablet regimen for patients with HIV infection comprising dolutegravir, abacavir and lamivudine. Overdoses with Triumeq have not been reported previously. We present a case of a 26-year-old man who presented to our hospital after intentionally ingesting 30 tablets of Triumeq. An intoxication with Triumeq can lead to several side effects. An overdose of abacavir and lamivudine can cause mitochondrial toxicity and lactic acidosis. An intoxication with dolutegravir appears to be relatively harmless. As Triumeq will be used on a regular basis as treatment for patients with HIV-1 infection, these intoxications are expected to be encountered more often.",

keywords = "POPULATION PHARMACOKINETICS, HIV, FUMARATE/EMTRICITABINE, DOLUTEGRAVIR",

author = "{van Dam}, Paul and {van Geffen}, Mark and Thomas Havenith and Dirk Posthouwer",

year = "2018",

doi = "10.3851/IMP3229",

language = "English",

volume = "23",

pages = "549--552",

journal = "Antiviral Therapy",

issn = "1359-6535",

publisher = "International Medical Press Ltd",

number = "6",

}

TY - JOUR

T1 - Intentional overdose of dolutegravir/abacavir/lamivudine (Triumeq) in a 26-year-old man

AU - van Dam, Paul

AU - van Geffen, Mark

AU - Havenith, Thomas

AU - Posthouwer, Dirk

PY - 2018

Y1 - 2018

N2 - Triumeq is a single-tablet regimen for patients with HIV infection comprising dolutegravir, abacavir and lamivudine. Overdoses with Triumeq have not been reported previously. We present a case of a 26-year-old man who presented to our hospital after intentionally ingesting 30 tablets of Triumeq. An intoxication with Triumeq can lead to several side effects. An overdose of abacavir and lamivudine can cause mitochondrial toxicity and lactic acidosis. An intoxication with dolutegravir appears to be relatively harmless. As Triumeq will be used on a regular basis as treatment for patients with HIV-1 infection, these intoxications are expected to be encountered more often.

AB - Triumeq is a single-tablet regimen for patients with HIV infection comprising dolutegravir, abacavir and lamivudine. Overdoses with Triumeq have not been reported previously. We present a case of a 26-year-old man who presented to our hospital after intentionally ingesting 30 tablets of Triumeq. An intoxication with Triumeq can lead to several side effects. An overdose of abacavir and lamivudine can cause mitochondrial toxicity and lactic acidosis. An intoxication with dolutegravir appears to be relatively harmless. As Triumeq will be used on a regular basis as treatment for patients with HIV-1 infection, these intoxications are expected to be encountered more often.

KW - POPULATION PHARMACOKINETICS

KW - HIV

KW - FUMARATE/EMTRICITABINE

KW - DOLUTEGRAVIR

U2 - 10.3851/IMP3229

DO - 10.3851/IMP3229

M3 - Editorial

C2 - 29533918

SN - 1359-6535

VL - 23

SP - 549

EP - 552

JO - Antiviral Therapy

JF - Antiviral Therapy

IS - 6

ER -